Research practice and innovative development of “disease⁃formula （effect）⁃syndrome”（Ⅲ）—Analysis on pathological basis of formula and syndrome of Xiayuxue Decoction in treatment of liver cirrhosis

JIANG Shili; MU Yongping; LIU Wei; LIU Ping

doi:10.16306/j.1008-861x.2023.03.001

您当前的位置：

首页 >

文章列表页 >

Research practice and innovative development of “disease⁃formula （effect）⁃syndrome”（Ⅲ）—Analysis on pathological basis of formula and syndrome of Xiayuxue Decoction in treatment of liver cirrhosis

Scholar Forum | 更新时间：2023-06-03

- Research practice and innovative development of “disease⁃formula （effect）⁃syndrome”（Ⅲ）—Analysis on pathological basis of formula and syndrome of Xiayuxue Decoction in treatment of liver cirrhosis
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 37, Issue 3, Pages: 1-7(2023)
- 作者机构：
  
  1.上海中医药大学附属曙光医院，上海市中医药研究院肝病研究所，肝肾疾病病证教育部重点实验室，上海市中医临床重点实验室（上海　201203）
  2.上海中医药大学交叉科学研究院（上海　201203）
- 作者简介：
- 基金信息：
- DOI：10.16306/j.1008-861x.2023.03.001
  CLC：
扫描看全文
蒋式骊,慕永平,刘伟等.“病⁃方（效）⁃证”的研究实践与创新发展（三）[J].上海中医药大学学报,2023,37(03):1-7.

JIANG Shili,MU Yongping,LIU Wei,et al.Research practice and innovative development of “disease⁃formula （effect）⁃syndrome”（Ⅲ）[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(03):1-7.
蒋式骊,慕永平,刘伟等.“病⁃方（效）⁃证”的研究实践与创新发展（三）[J].上海中医药大学学报,2023,37(03):1-7. DOI： 10.16306/j.1008-861x.2023.03.001.

JIANG Shili,MU Yongping,LIU Wei,et al.Research practice and innovative development of “disease⁃formula （effect）⁃syndrome”（Ⅲ）[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2023,37(03):1-7. DOI： 10.16306/j.1008-861x.2023.03.001.

摘要

基于肝炎后肝硬化气虚血瘀的核心病机，本课题组提出并论证了“血瘀为积之标，虚损为积之本”的肝硬化中医病机理论。采用不同功效中医古典方剂干预治疗肝硬化多种模型的研究表明，祛瘀的下瘀血汤干预肝硬化的作用特征是针对纤维结缔组织异常沉积、肝窦毛细血管化和肝血管异常新生。其作用机制包括下调金属蛋白酶组织抑制物表达，提高金属蛋白酶活性，促进病理性异常沉积胶原的降解，抑制肝星状细胞活化并诱导其凋亡，改善肝窦毛细血管化和抑制血管增生等，是下瘀血汤“治标”的作用特征。本文从“病-方（效）-证”相关的实验结果，解析了肝硬化血瘀病机的关键病理学基础主要为肝脏纤维结缔组织异常沉积和活化的星状细胞增殖，还包括胶原降解活性低下、肝窦内皮细胞开窗缺失、内皮下基底膜形成以及毛细血管化增加。以上为明确祛瘀方剂（如下瘀血汤）治疗现代疾病所针对的适应证（病理指征）提供了参考依据，并有助于促进临床转化应用。

Abstract

Based on the core pathogenesis of qi deficiency and blood stasis in cirrhosis after hepatitis， the theory of traditional Chinese medicine （TCM） pathogenesis of liver cirrhosis “blood stasis is the superficial sign of lump accumulation， and intrinsic deficiency is the root cause of lump accumulation” is proposed and discussed. Studies using multiple liver cirrhosis models under intervention of classical TCM formulas with different function and effects have shown that the role of removing stasis by Xiayuxue Decoction against liver cirrhosis is characterized by targeting abnormal deposition of fibrous connective tissue， hepatic sinus capillarization and abnormal angiogenesis in the liver. The mechanism of Xiayuxue Decoction includes downregulating the expression of tissue inhibitors of metalloproteinases， increasing the activities of matrix metalloproteinases， promoting the degradation of pathological deposited collagens， inhibiting the activation of hepatic stellate cells and inducing their apoptosis， improving the hepatic sinus capillarization and inhibiting angiogenesis， which are its charcteristics of “treating symptoms”. Analyzing the experimental results related to “disease-formula （effect）-syndrome” reveals that the key pathological basis of the blood stasis in liver cirrhosis is mainly abnormal deposition of liver fibrous connective tissue and proliferation of activated stellate cells， low collagen degradation activity， lack of liver sinusoidal endothelial cell fenestration and formation of subendothelial basement membrane， and increased capillarization. The above provides a reference for clarifying the disease indications （pathological indications） targeted by stasis-dispelling formulas （such as Xiayuxue Decoction）， and helps to promote clinical translational application.

关键词

证候病机方证病理学肝硬化下瘀血汤肝星状细胞凋亡肝窦毛细血管化胶原纤维降解

Keywords

syndrome pathogenesispathology of formulas and patternsliver cirrhosisXiayuxue Decoctionapoptosis of hepatic stellate cellshepatic sinus capillarizationcollagen fiber degradation

references

慕永平，刘平.“病-方（效）-证”的研究实践与创新发展（一）——黄芪汤治疗肝硬化的方证病理学基础探析［J］.上海中医药大学学报，2022， 36（5）： 6-11，33.

MU Y P，LIU P.Research practice and innovative development of “disease-formula （effect）-syndrome”（I）—analysis on pathological basis of formula and syndrome of Huangqi Decoction in treatment of liver cirrhosis［J］. Journal of Shanghai University of Traditional Chinese Medicine， 2022， 36（5）： 6-11， 33.

陈佳美，慕永平，刘平.“病-方（效）-证”的研究实践与创新发展（二）——一贯煎治疗肝硬化的方证病理学基础探析［J］.上海中医药大学学报，2023， 37（2）： 1-6，21.

CHEN J M，MU Y P，LIU P.Research practice and innovative development of “disease-formula （effect）-syndrome”（Ⅱ）—Analysis on pathological basis of formulas and patterns of Yiguanjian in treatment of liver cirrhosis［J］. Journal of Shanghai University of Traditional Chinese Medicine， 2023， 37（2）： 1-6，21.

戴克敏.姜春华运用下瘀血汤的经验［J］.辽宁中医杂志，1986， 13（7）： 1-2.

DAI K M.Jiang Chunhua’s Experience in Using Xiayuxue Decoction［J］. Liaoning Journal of Traditional Chinese Medicine， 1986， 13（7）： 1-2.

单书健，陈子华.古今名医临证金鉴-黄疸胁痛臌胀卷（下）［M］.北京：中国中医药出版社，1999： 265-405．

SHAN S J， CHEN Z H.Ancient and Modern Doctors Clinical Experience—Monograph on Jaundice， hypochondriac pain， and tympanites（Part 2）［M］. Beijing：China Press of Traditional Chinese Medicine， 1999： 265-405．

葛均波，徐永健，王辰.内科学［M］. 9版.北京：人民卫生出版社，2018： 405-406.

GE J B， XU Y J， WANG C. Internal Medicine［M］.9th Edition.Beijing： People’s Medical Publishing House， 2018： 405-406.

JANGRA A，KOTHARI A，SARMA P，et al.Recent Advancements in Antifibrotic Therapies for Regression of Liver Fibrosis［J］. Cells，2022， 11（9）： 1500.

都广礼，刘平，王磊，等.下瘀血汤抗猪血清免疫性肝纤维化方证相关的药效学研究［J］.中国实验方剂学杂志，2007， 13（6）： 30-33．

DU G L，LIU P，WANG L，et al. Relationship Between Traditional Medical Formulae and Syndrome Based Pharmacological Study of Xiayuxue Decoction against Porcine Serum Induced Liver Fibrosis in Rats［J］. Chinese Journal of Experimental Traditional Medical Formulae， 2007， 13（6）： 30-33.

慕永平，刘平，都广礼，等.祛瘀和养阴不同功效中医经典方剂抑制CCl4诱导大鼠肝硬化的作用机制［J］.自然科学进展，2006， 16（9）： 1101-1108．

MU Y P， LIU P， DU G L，et al.The Mechanism of Traditional Chinese Medicine Classic Prescriptions with Different Effects on Removing Blood Stasis and Nourishing Yin in Inhibiting CCl4-Induced Liver Cirrhosis in Rats［J］.Progress in Natural Science，2006， 16（9）： 1101-1108．

慕永平，刘平，龙爱华，等. CCl4大鼠肝硬化成型阶段中医方证病机的研究［J］.中国中西医结合杂志，2006， 26（4）： 344-347.

MU Y P， LIU P， LONG A H，et al.Study on pathogenesis of CCl4 induced cirrhosis formation in rats based on the recipe used［J］.Chinese Journal of Integrative Medicine，2006， 26（4）： 344-347.

都广礼，刘平，王磊，等.猪血清肝纤维化大鼠肝组织基质金属蛋白酶-9/13和基质金属蛋白酶组织抑制因子-1/2表达的动态变化及下瘀血汤对其影响［J］.中国实验方剂学杂志，2009， 15（11）： 48-51.

DU G L，LIU P，WANG L，et al.Expression of Matrix Metalloproteinase 9/13（MMP-9/13）and Tissue Inhibitor of Metalloproteinase 1/2（TIMP-1/2）in Liver Fibrosis Induced by Porcine Serum and Xiayuxue Decoction on It［J］.Chinese Journal of Experimental Traditional Medical Formulae， 2009， 15（11）： 48-51.

都广礼，陈德兴，张艳，等.肝纤维化大鼠肝组织基质金属蛋白酶9及其抑制因子1基因表达的动态变化及下瘀血汤对其影响［J］.中国中西医结合消化杂志，2010， 18（1）： 1-4.

DU G L， CHEN D X， ZHANG Y， et al. Dynamic gene expression of matrix metalloproteinases-9 and tissue inhibitor of metalloproteinase-1 in rat fibrotic liver tissue and effect of Xiayuexue Decoction［J］.Chinese Journal of Integrated Traditional and Western Medicine on Digestion， 2010， 18（1）： 1-4.

FRIEDMAN S L，PINZANI M.Hepatic fibrosis 2022：Unmet needs and a blueprint for the future［J］.Hepatology， 2022， 75（2）： 473-488.

FRIEDMAN S L. Hepatic stellate cells： protean， multifunctional， and enigmatic cells of the liver［J］.Physiol Rev， 2008， 88（1）： 125-172.

ATZORI L， POLI G， PERRA A. Hepatic stellate cell： a star cell in the liver［J］. Int J Biochem Cell Biol， 2009， 41（8-9）： 1639-1642.

LIU C， CAI J， CHENG Z， et al.Xiayuxue decoction reduces renal injury by promoting macrophage apoptosis in hepatic cirrhotic rats［J］. Genet Mol Res， 2015， 14（3）： 10760-10773.

TAO L， MA W T， WU L，et al.Glial cell line-derived neurotrophic factor （GDNF） mediates hepatic stellate cell activation via ALK5/Smad signalling［J］. Gut， 2019， 68（12）： 2214-2227.

张玮，杨广越，沈东晓，等.下瘀血汤抑制胶质细胞源性神经营养因子抗肝纤维化的作用机制［J］.临床肝胆病杂志，2021， 37（3）： 575-581.

ZHANG W， YANG G Y， SHEN D X， et al. Mechanism of action of Xiayuxue decoction in inhibiting liver fibrosis by regulating glial cell line-derived neurotrophic factor［J］. J Clin Hepatol， 2021， 37（3）： 575-581.

ZHANG L J， SUN M Y， NING B B， et al. Xiayuxue Decoction （下瘀血汤） attenuates hepatic stellate cell activation and sinusoidal endothelium defenestration in CCl4-induced fibrotic liver of mice［J］. Chin J Integr Med， 2014， 20（7）： 516-523.

ZHANG D Q，ZHANG L J，CHEN G F，et al.Hepatoprotective effect of Xiayuxue decoction ethyl acetate fraction against carbon tetrachloride-induced liver fibrosis in mice via inducing apoptosis and suppressing activation of hepatic stellate cells［J］. Pharm Biol， 2020， 58（1）： 1229-1243.

DELEVE L D. Liver sinusoidal endothelial cells in hepatic fibrosis［J］. Hepatology， 2015， 61（5）： 1740-1746.

MEJIAS M， GARCI-PRAS E， TIANI C， et al. Beneficial effects of sorafenib on splanchnic， intrahepatic， and portocollateral circulations in portal hypertensive and cirrhotic rats［J］.Hepatology， 2009， 49（4）： 1245-1256.

都金星，刘平，孙明瑜，等.下瘀血汤对四氯化碳诱导的肝硬化大鼠肝脏血管新生的抑制作用［J］.中西医结合学报，2011， 9（8）： 878-886.

DU J X，LIU P，SUN M Y，et al.Chinese herbal medicine Xiayuxue Decoction inhibits liver angiogenesis in rats with carbon tetrachloride-induced liver fibrosis［J］.Journal of Chinese Integrative Medicine， 2011， 9（8）： 878-886.

HABIB A，CHOKR D，WAN J，et al.Inhibition of monoacylglycerol lipase， an anti-inflammatory and antifibrogenic strategy in the liver［J］. Gut， 2019， 68（3）： 522-532．

DAMOISEAUX J G， DÖPP E A， CALAME W， et al.Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1［J］. Immunology， 1994， 83（1）： 140-147.

KUMAGAI K， KIYOSAWA N， ITO K， et al. Influence of Kupffer cell inactivation on cycloheximide-induced hepatic injury［J］. Toxicology， 2007， 241（3）： 106-118.

刘乐平，陆芩，王晓斌，等.下瘀血汤对肝硬化大鼠肝组织CD68和CD163蛋白表达的影响［J］.中国药理学与毒理学杂志，2014， 28（1）： 35-41.

LIU L P， LU Q， WANG X B，et al.Effect of Xiayuxue decoction on CD68 and CD163 protein expression in liver tissue of rats with liver cirrhosis［J］.Chinese Journal of Pharmacology and Toxicology， 2014， 28（1）： 35-41.

MA W T， TAO L，ZHANG W， et al.Xia-Yu-Xue Decoction inhibits intestinal epithelial cell apoptosis in CCl4-induced liver fibrosis［J］. Cell Physiol Biochem， 2017， 44（1）： 333-344.

沈东晓，马文婷，吴柳，等.下瘀血汤抑制胰腺巨噬细胞浸润改善肝纤维化的机制研究［J］.上海中医药大学学报，2019， 33（2）： 66-72.

SHEN D X， MA W T， WU L，et al. Mechanism of Xiayuxue Decoction on improving liver fibrosis by inhibiting pancreatic macrophage infiltration［J］.Journal of Shanghai University of Traditional Chinese Medicine， 2019， 33（2）： 66-72.

吴柳，杨广越，张洁，等.下瘀血汤下调NLRP3改善高脂饮食诱导小鼠非酒精性脂肪性肝炎［J］.中国中西医结合杂志，2020， 40（10）： 1202-1208.

WU L，YANG G Y， ZHANG J， et al.Xiayuxue Decoction Improved HFD-induced-Nonalcoholic Steatohepatitis Mice by Down-regulating NLRP3［J］.Chinese Journal of Integrated Traditional and Western Medicine， 2020， 40（10）： 1202-1208.

赵玲，胡昌江，潘新，等.下瘀血汤中大黄生熟互换对热结血瘀模型大鼠血管内皮功能及微循环的影响［J］.药物评价研究，2014， 37（5）： 413-416.

ZHAO L，HU C J， PAN X， et al. Effect of raw/stewed Rhubarb in Xiayuxue Decoction on vascular endothelial function and microcirculation of rats with heat accumulation of blood stasis［J］.Drug Evaluation Research， 2014， 37（5）： 413-416.

张定棋，徐莹，杨海琳，等.不同制法下瘀血汤对CCl4诱导大鼠肝纤维化的影响［J］.中国实验方剂学杂志，2020， 26（5）： 18-25.

ZHANG D Q， XU Y， YANG H L，et al. Effect of Xiayuxue Tang with Different Processing Method on CCl4-induced Hepatic Fibrosis in Rats［J］. Chinese Journal of Experimental Traditional Medical Formulae， 2020， 26（5）： 18-25.

ZHANG C C， ZHANG D Q，WANG Y L，et al. Pharmacokinetics and anti-liver fibrosis characteristics of amygdalin： Key role of the deglycosylated metabolite prunasin［J］. Phytomedicine， 2022， 99： 154018.

李雪梅，冯琴，彭景华，等.苦杏仁苷对二甲基亚硝胺诱导的大鼠肝纤维化的防治作用［J］.中西医结合肝病杂志，2011， 21（4）： 221-223.

LI X M， FENG Q， PENG J H，et al.Prevention effects of amygdalin on rat fibrosis induced by dimethylnitrosamine［J］. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases， 2011， 21（4）： 221-223.

李兴暖，韩雅莉.地鳖虫纤溶活性蛋白组分抑制血管的生成［J］.动物学报，2007， 53（1）： 135-142.

LI X N， HAN Y L. Antiangiogenesis of fibrinolyric protein from Eupolyphaga sinesis Walker［J］. Acta Zoologica Sinica， 2007， 53（1）： 135-142.

陈少丽，都广礼，丁娜，等.下瘀血汤全药与组分处方抗猪血清肝纤维化的比较研究［J］.中国实验方剂学杂志，2012， 18（1）： 154-157.

CHEN S L，DU G L，DING N，et al.Comparative Study of Xiayuxue Decoction and Its Ingredients Recipe Against Porcine Serum Induced Liver Fibrosis in Rats［J］. Chinese Journal of Experimental Traditional Medical Formulae， 2012， 18（1）： 154-157.

牛楠，郝海涛.中药复方化学成分的研究进展［J］.中国药业，2011， 20（7）： 77-79.

NIU N，HAO H T. Research progress on the chemical components of traditional Chinese medicine prescriptions［J］.China Pharmaceuticals， 2011， 20（7）： 77-79.

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research practice and innovative development of “disease⁃formula （effect）⁃syndrome” （Ⅱ） —Analysis on pathological basis of formula and syndrome of Yiguanjian in treatment of liver cirrhosis

Research practice and innovative development of “disease⁃formula （effect）⁃syndrome” （Ⅰ）Analysis on pathological basis of formula and syndrome of Huangqi Decoction in treatment of liver cirrhosis

Evaluation on Mental State of Patients with Liver Cirrhosis and Its Relationship with TCM Syndromes Based on Psychiatric Scale

Mechanism of Xiayuxue Decoction on improving liver fibrosis by inhibiting pancreatic macrophage infiltration

Related Author

No data

Related Institution

Cross Science Research Institute of Shanghai University of Traditional Chinese Medicine

Department of Liver Cirrhosis,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Institute of Liver Diseases,Shanghai University of Traditional Chinese Medicine

Key Laboratory of Education Ministry for Liver and Kidney Diseases

Central Laboratory,Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

⁰